Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018224595) VACCINE COMPRISING CLOSTRIDIUM TOXOIDS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/224595 International Application No.: PCT/EP2018/065025
Publication Date: 13.12.2018 International Filing Date: 07.06.2018
IPC:
A61K 39/08 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
02
Bacterial antigens
08
Clostridium, e.g. Clostridium tetani
Applicants:
HIPRA SCIENTIFIC, S.L.U. [ES/ES]; Avda. La Selva, 135 17170 AMER, ES
Inventors:
GIBERT PÉREZ, Xavier; ES
SITJÀ ARNAU, Marta; ES
Agent:
ZBM PATENTS - ZEA, BARLOCCI & MARKVARDSEN; Pl. Catalunya, 1 2nd floor 08002 BARCELONA, ES
Priority Data:
17382358.409.06.2017EP
Title (EN) VACCINE COMPRISING CLOSTRIDIUM TOXOIDS
(FR) VACCIN COMPRENANT DES ANATOXINES DE CLOSTRIDIUM
Abstract:
(EN) The present invention relates to an immunogenic composition comprising one or more C. difficile toxoid for use in a medicament for animals. The invention also encompasses an immunogenic composition comprising one or more C. difficile A toxoid and one or more C. difficile B toxoid and one or more C. perfringens Type A toxoid. The invention also encompasses vaccines comprising said immunogenic compositions, vaccines for use in the treatment and/or prevention of disease caused by C. difficile and C. perfringens, and kits thereof.
(FR) La présente invention concerne une composition immunogène comprenant une ou plusieurs anatoxines de C. difficile à utiliser dans un médicament pour animaux. L'invention concerne également une composition immunogène comprenant une ou plusieurs anatoxines de C. difficile type A et une ou plusieurs anatoxines de C. difficile type B et une ou plusieurs anatoxines de C. perfringens Type A. L'invention concerne également des vaccins comprenant lesdites compositions immunogènes, des vaccins destinés à être utilisés dans le traitement et/ou la prévention d'une maladie provoquée par C difficile et C perfringens, et des kits associés.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)